IA
CRBP icon

IFP Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

IFP Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19
Closed -$240 – 4913
2025
Q3 		$240 Buy
19
+4
+27% +$38 ﹤0.01% 4360
2025
Q2 		$213 Buy
+15
New +$109 ﹤0.01% 4618
2025
Q1 		– Sell
-1
Closed -$12 – 4382
2024
Q4 		$12 Buy
+1
New +$17 ﹤0.01% 4513
2024
Q2 		– Sell
-3
Closed -$118 – 3248
2024
Q1 		$118 Hold
3
– – ﹤0.01% 3057
2023
Q4 		$18 Hold
3
– – ﹤0.01% 3010
2023
Q3 		$20 Hold
3
– – ﹤0.01% 3260
2023
Q2 		$24 Sell
3
-100
-97% -$899 ﹤0.01% 3414
2023
Q1 		$605 Buy
103
+90
+692% +$394 ﹤0.01% 3163
2022
Q4 		$3K Buy
13
+3
+30% +$12 ﹤0.01% 3989
2022
Q3 		$2K Hold
10
– – ﹤0.01% 4334
2022
Q2 		$2K Hold
10
– – ﹤0.01% 4099
2022
Q1 		$2K Buy
10
+7
+233% +$93 ﹤0.01% 4099
2021
Q4 		$1K Hold
3
– – ﹤0.01% 2965
2021
Q3 		$1K Buy
+3
New +$118 ﹤0.01% 2999
2020
Q4 		– Sell
-79
Closed -$2.95K – 2972
2020
Q3 		$4K Sell
79
-213
-73% -$38.6K ﹤0.01% 2251
2020
Q2 		$69K Buy
292
+26
+10% +$5.25K 0.01% 1068
2020
Q1 		$45K Hold
266
– – ﹤0.01% 1168
2019
Q4 		$44K Sell
266
-50
-16% -$7.39K ﹤0.01% 1308
2019
Q3 		$48K Buy
+316
New +$55K ﹤0.01% 1385
2019
Q1 		$4K Sell
19
-53,600
-100% -$11.8M ﹤0.01% 1918
2018
Q4 		$9.46M Buy
53,619
+3,411
+7% +$681K 0.58% 27
2018
Q3 		$11.4M Buy
50,208
+181
+0.4% +$29.3K 0.46% 37
2018
Q2 		$7.58M Buy
50,027
+16,667
+50% +$3.03M 0.32% 66
2018
Q1 		$7.11M Hold
33,360
– – 0.32% 64
2017
Q4 		$7.11M Sell
33,360
-8
-0% -$1.71K 0.32% 64
2017
Q3 		$7.16M Hold
33,368
– – 0.28% 73
2017
Q2 		$6.31M Hold
33,368
– – 0.27% 76
2017
Q1 		$8.26M Buy
33,368
+15,851
+90% +$3.89M 0.36% 56
2016
Q4 		$4.44M Buy
17,517
+7,517
+75% +$1.72M 0.21% 103
2016
Q3 		$2.04M Buy
+10,000
New +$1.24M 0.11% 217
2016
Q2 		– Sell
-19
Closed -$4K – 3863
2016
Q1 		$4K Buy
+19
New +$838 ﹤0.01% 1918

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

IFP Advisors's CRBP Position: Q4 2025 in Review

IFP Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q4 2025, closing a stake of 19 shares — an estimated $240 sold.

IFP Advisors first reported a position in CRBP in Q1 2016 and held it in 31 quarters. The position peaked at $11.4M in Q3 2018. 101 funds tracked by Wall St. Rank hold CRBP as of Q4 2025.

  • IFP Advisors reported no remaining Corbus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • IFP Advisors sold 19 Corbus Pharmaceuticals shares in Q4 2025, an estimated $240.
  • IFP Advisors first reported a position in Corbus Pharmaceuticals in Q1 2016 and held it in 31 quarters.
  • IFP Advisors's Corbus Pharmaceuticals position peaked at $11.4M in Q3 2018.
  • 101 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2025.

Based on IFP Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.